United Therapeutics
UTHR
399 hedge funds and large institutions have $5.61B invested in United Therapeutics in 2016 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 174 increasing their positions, 114 reducing their positions, and 52 closing their positions.
53% more call options, than puts
Call options by funds: $45.2M | Put options by funds: $29.5M
53% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 114
27% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 52
3% more funds holding
Funds holding: 387 → 399 (+12)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
47% less capital invested
Capital invested by funds: $10.7B → $5.61B (-$5.06B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$173M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$60.2M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$50.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.5M |
| 5 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$29.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$129M |
| 2 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$104M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$84.8M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$61.5M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$61M |
UTHR Hedge Fund Activity: Q1 2016 in Review
399 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2016, worth a combined $5.61B — down 47% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new UTHR positions and 52 closed out — a net gain of 14 holders — while 174 added to existing stakes and 114 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $173M. The largest seller was BlackRock Advisors, cutting an estimated $129M.
- 399 institutional investors held United Therapeutics (UTHR) as of Q1 2016, up from 387 in Q4 2015.
- Funds reported $5.61B of United Therapeutics stock for Q1 2016, down 47% quarter-over-quarter.
- 66 funds opened new United Therapeutics positions in Q1 2016 and 52 closed out, a net change of +14 holders.
- The largest United Therapeutics buyer in Q1 2016 was Scopia Capital Management, an estimated $173M added.
- The largest United Therapeutics seller in Q1 2016 was BlackRock Advisors, an estimated $129M sold.
Based on aggregated 13F filings for Q1 2016.